Stay updated on Nivolumab±Ipilimumab in Ovarian & Clear Cell Carcinomas Clinical Trial
Sign up to get notified when there's something new on the Nivolumab±Ipilimumab in Ovarian & Clear Cell Carcinomas Clinical Trial page.

Latest updates to the Nivolumab±Ipilimumab in Ovarian & Clear Cell Carcinomas Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedAdded primary peritoneal carcinoma and fallopian tube cancer to the listed conditions, and introduced the Genetic and Rare Diseases Information Center as a new resource. Updated page revision to v3.4.2 and removed the prior funding-status notice (v3.4.1).SummaryDifference0.6%

- Check41 days agoChange DetectedThe page adds a site-wide government funding/status notice and updates the site revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedAdded 'Show glossary' and updated footer labels, including 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and the revision note 'Revision: v3.4.0' (replacing v3.3.4). These changes do not modify core study data or essential information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing Revision: v3.3.3; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a consolidated Locations section listing Illinois and Rhode Island sites. Removed the separate Illinois Locations and Rhode Island Locations sections as part of revision v3.3.3.SummaryDifference0.3%

Stay in the know with updates to Nivolumab±Ipilimumab in Ovarian & Clear Cell Carcinomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab±Ipilimumab in Ovarian & Clear Cell Carcinomas Clinical Trial page.